News

The approval of ivosidenib fills an unmet need for patients with relapsed or refractory acute myeloid leukemia who have an IDH1 genetic mutation.
Gene-editing technology could lead to new targeted therapies and help clinicians catch developing cancers before they metastasize.
Genentech announced that the FDA has granted Breakthrough Therapy Designation to atezolizumab (Tecentriq) in combination with bevacizumab (Avastin) as a first-line treatment for patients with the most common form of liver cancer.
Top news of the day from across the health care landscape.
Top news of the week from Specialty Pharmacy Times.
Based on 2017 FDA research, the delayed market launch of nine biosimilars represented $4.5 billion in potential savings.
The onus to have properly-trained pharmacists has shifted from the specialty pharmacy to the individual.

Product News

Granix is a human granulocyte factor produced in a bioreactor using recombinant DNA technology.
Complera treats HIV infection in previously untreated adults with a viral load of 100,000 copies/mL or less.
Repatha (evolocumab) treats primary hyperlipidemia in combination with dietary measures and maximally tolerated doses of statins.
Stribild (elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate) is approved for treatment of HIV-1 infection.

Most Popular

Company Profile >
Contributors >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Advertise
Careers
Contact Us
Terms & Conditions
Privacy
MJH Associates >
Pharmacy Times
OTCGuide
American Journal of Managed Care
Cure
MD Magazine
ONCLive
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2018
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.
 

$vacMongoViewPlus$